Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma as CEO to Drive Growth

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, has announced the appointment of Eric Poma, PhD, as its new chief executive officer and a member of the board of directors. This move is seen as a strategic effort to leverage Dr. Poma's extensive experience in oncology, fundraising, and strategic partnerships to propel the company's next phase of growth. Dr. Poma's leadership is expected to guide Calidi's pioneering targeted antitumor virotherapies through clinical development and towards commercialization, enhancing the company's position in the competitive biotech landscape.

The significance of this appointment lies in Calidi Biotherapeutics' innovative approach to cancer treatment. The company's proprietary stem cell-based platforms are designed to deliver oncolytic viruses directly to tumors, offering a novel method to combat high-grade gliomas and solid tumors. With Dr. Poma at the helm, Calidi is poised to accelerate the development of its therapies, which could potentially transform cancer treatment by improving efficacy and patient safety. This development is crucial for the biotech industry and patients worldwide, as it represents a step forward in the fight against cancer, highlighting the importance of experienced leadership in bringing groundbreaking therapies to market.